Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Neurobehavioral Disinhibition
Interventions
Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
54
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Conditions
Healthy
Interventions
AVP-923, AVP-786, Itraconazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Genotype on LY2216684

NCT01460381
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Disinhibition Syndrome
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Healthy Volunteer
Interventions
NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Comparing AVP-786 With AVP-923

NCT02336347
Conditions
Healthy Volunteer
Interventions
AVP-786, AVP-923
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Rate Control, Ablation Therapy, Rhythm control
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
171
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Conditions
Schizophrenia
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
Completed Phase 1Phase 2 Interventional Results available

Impact of Nuedexta on Bulbar Physiology and Function in ALS

NCT03883581
Conditions
Amyotrophic Lateral Sclerosis
Interventions
dextromethorphan HBr and quinidine sulfate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Gainesville, Florida
Conditions
Arrhythmia
Interventions
quinidine, no therapy
Drug
Lead sponsor
International Registry of Asymptomatic Brugada Syndrome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Conditions
Schizophrenia
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Cerritos, California • Garden Grove, California • National City, California + 14 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556
Conditions
Healthy
Interventions
Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Cypress, California • South Miami, Florida • San Antonio, Texas
Conditions
Healthy
Interventions
Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Conditions
COVID-19
Interventions
EDP-235, Itraconazole, Carbamazepine, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Intermittent Explosive Disorder
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more
Conditions
RSV Infection
Interventions
EDP-938, Itraconazole, Rifampin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon